Navigation Links
bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Date:1/31/2012

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, has introduced a new product line of high medical value biomarkers for response, resistance and pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, a new paradigm in cancer management, partners accurate diagnosis of primary tumor site and predictive biomarkers to drive targeted therapy.  The PRECIS tests help oncologists predict potential response and evaluate underlying disease pathways as they consider targeted therapies.

The PRECIS product line includes biomarker profiles for non-small cell lung cancer and colorectal cancer and detects clinically relevant tumor biomarkers EGFR, ALK rearrangement, KRAS, BRAF, c-MET, PIK3CA and 10q23 deletion to aid in characterizing disease behavior and therapeutic effectiveness.

"An unmet need for targeted therapy treatments in metastatic cancer is accurate tumor classification plus knowledge of the activated signal transduction pathway driving cancer growth," said Richard Ding, Chief Executive Officer of bioTheranostics.  "The use of CancerTYPE ID®, the leading molecular classifier to aid physicians in ascertaining tumor origin, and PRECIS Precision Medicine biomarkers has significant potential to improve cancer diagnosis and help oncologists efficiently formulate an optimal personalized treatment plan.

"The launch of PRECIS is a key milestone for bioTheranostics as the company moves to become an integrated diagnostic solution provider in cancer management," said Ding.  "The PRECIS test menu provides cutting-edge tumor pathway information on therapeutic prediction and resistance mechanisms.

"We will continue to expand our testing menu as more predictive biomarkers demonstrate their clinical utility.  Our physician customers have also indicated that the turnaround time for the test results was important in their clinical decisions.  Our lab will respond to our client's needs by providing PRECIS test results within 7 to 10 days," Ding concluded.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin and PRECIS Precision Medicine by bioTheranostics, which includes clinically relevant oncology biomarkers for comprehensive cancer management.

For more information, call 1-858-587-5870 or visit www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached euro 1.427 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

FOR INFORMATION:

bioTheranostics
Tim Schofield
Tel: + 1 858 587 5890
tim.schofield@biotheranostics.com

bioMerieux
Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14
media@eu.biomerieux.com


'/>"/>
SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. bioTheranostics Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
2. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
3. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
4. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
5. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
6. Neogen Launches Fully Quantitative Lateral Flow Test for DON
7. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
8. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
11. Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. ... Disease drug candidate, code-named "KM-819." KM-819 is an orally active small molecule ... in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study ...
(Date:12/20/2018)... ... , ... New Year’s brings reflection and desire to improve for individuals and ... (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, suggests five ... Device Regulation (MDR), digital health, and big data are just a few of the ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial ... (human) ingredient. This has been part of their strategic plan and an important ... certification creates custom fermentation opportunities for MDG within the $44 Billion human probiotic ...
Breaking Biology Technology:
(Date:1/4/2019)... ... January 03, 2019 , ... Over the last ... their drug discovery research workflows with biology ranging from single cell-type spheroids to ... in vitro studies, they create several challenges that need to be overcome in ...
(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... , ... InTouchMD’s flagship product, Pulse , has been honored by PM360 ... is featuring the recognition in its 7th annual Innovations issue, created for purpose of ... medical device industries. , “This recognition comes at an exciting time for Pulse as ...
Breaking Biology News(10 mins):